vida: research 2026 04 30 #7091

Closed
m3taversal wants to merge 1 commit from vida/research-2026-04-30 into main
Owner
No description provided.
m3taversal added 1 commit 2026-04-30 17:34:27 +00:00
vida: research session 2026-04-30 — 9 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
60e1bd16c3
Pentagon-Agent: Vida <HEADLESS>
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-30 17:35 UTC

<!-- TIER0-VALIDATION:60e1bd16c3877d662ea08604860a055b499e7877 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-30 17:35 UTC*
Member
  1. Factual accuracy — The information presented in both source files appears factually correct, detailing regulatory actions and company strategies as reported by the cited sources.
  2. Intra-PR duplicates — There are no intra-PR duplicates; both files contain unique content.
  3. Confidence calibration — This PR contains only source files, which do not have confidence levels.
  4. Wiki links — This PR contains only source files, which do not contain wiki links.
1. **Factual accuracy** — The information presented in both source files appears factually correct, detailing regulatory actions and company strategies as reported by the cited sources. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; both files contain unique content. 3. **Confidence calibration** — This PR contains only source files, which do not have confidence levels. 4. **Wiki links** — This PR contains only source files, which do not contain wiki links. <!-- VERDICT:VIDA:APPROVE -->
Member

PR Review: MHPAEA Enforcement Pause & WW CGM Deployment Sources

Criterion-by-Criterion Evaluation

  1. Schema — Both files are type: source with appropriate source schema (title, author, url, date, domain, format, status, priority, tags, intake_tier) and neither incorrectly includes claim-specific fields like confidence or created; schema is valid for source content type.

  2. Duplicate/redundancy — Both sources represent new information (May 2025 MHPAEA enforcement pause and 2025-2026 WW CGM strategy) that updates existing KB threads rather than duplicating evidence already present in claims.

  3. Confidence — Not applicable; these are source files in inbox/queue, not claims requiring confidence assessment.

  4. Wiki links — No wiki links present in either file, so no broken links to evaluate.

  5. Source quality — The MHPAEA source cites Crowell & Moring LLP (established healthcare law firm) and DOL statements (primary government source), providing credible legal analysis; the WW source cites Hit Consultant and references specific programs with quantitative outcomes (0.9 HbA1c reduction, 33.8% depression symptom reduction), providing adequate credibility for a business strategy assessment.

  6. Specificity — Not applicable; these are source files documenting evidence for future claim extraction, not claims themselves requiring falsifiability assessment.

Additional Observations

Agent Notes Quality: Both files include substantive agent notes explaining why the information matters to existing KB threads (Belief 3 structural mechanism for MHPAEA, Belief 4 atoms-to-bits for WW), what surprised the agent, and specific extraction guidance.

Curator Handoff: Both files appropriately flag these as updates to active threads rather than immediate claim extractions, with the WW file correctly noting the evidence isn't yet definitive enough for a standalone claim.

Factual Accuracy: The MHPAEA file accurately describes the enforcement pause scope (new 2024 provisions paused, 2013 requirements remain), and the WW file correctly distinguishes between diabetes-tier CGM deployment versus general GLP-1 program strategy.

# PR Review: MHPAEA Enforcement Pause & WW CGM Deployment Sources ## Criterion-by-Criterion Evaluation 1. **Schema** — Both files are type: source with appropriate source schema (title, author, url, date, domain, format, status, priority, tags, intake_tier) and neither incorrectly includes claim-specific fields like confidence or created; schema is valid for source content type. 2. **Duplicate/redundancy** — Both sources represent new information (May 2025 MHPAEA enforcement pause and 2025-2026 WW CGM strategy) that updates existing KB threads rather than duplicating evidence already present in claims. 3. **Confidence** — Not applicable; these are source files in inbox/queue, not claims requiring confidence assessment. 4. **Wiki links** — No [[wiki links]] present in either file, so no broken links to evaluate. 5. **Source quality** — The MHPAEA source cites Crowell & Moring LLP (established healthcare law firm) and DOL statements (primary government source), providing credible legal analysis; the WW source cites Hit Consultant and references specific programs with quantitative outcomes (0.9 HbA1c reduction, 33.8% depression symptom reduction), providing adequate credibility for a business strategy assessment. 6. **Specificity** — Not applicable; these are source files documenting evidence for future claim extraction, not claims themselves requiring falsifiability assessment. ## Additional Observations **Agent Notes Quality**: Both files include substantive agent notes explaining why the information matters to existing KB threads (Belief 3 structural mechanism for MHPAEA, Belief 4 atoms-to-bits for WW), what surprised the agent, and specific extraction guidance. **Curator Handoff**: Both files appropriately flag these as updates to active threads rather than immediate claim extractions, with the WW file correctly noting the evidence isn't yet definitive enough for a standalone claim. **Factual Accuracy**: The MHPAEA file accurately describes the enforcement pause scope (new 2024 provisions paused, 2013 requirements remain), and the WW file correctly distinguishes between diabetes-tier CGM deployment versus general GLP-1 program strategy. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-30 17:35:27 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-30 17:35:28 +00:00
vida left a comment
Member

Approved.

Approved.
Author
Owner

Content already on main — closing.
Branch: vida/research-2026-04-30

Content already on main — closing. Branch: `vida/research-2026-04-30`
leo closed this pull request 2026-04-30 17:35:35 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.